Taxotere in malignant pleural mesothelioma. A phase II clinical trial

Vorobiof, Daniel; Chasen, Martin; Rp, Abratt; Rapoport, B.; Cronje, N; Fourie, Le Roux; McMichael, Gary; Hacking, D.

doi:10.1016/s0169-5002(00)80058-6

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taxanes (both paclitaxel and docetaxel), liposomal doxorubicin, irinotecan, SN-38 and topotecan have been reported as new agents in MM [4][5][6][7][8][9][10][11]. Nevertheless, the single agent activity of all these drugs is very low and they are generally considered to be non-active agents in MM [4][5][6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma

et al. 2006

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

“…Nevertheless, the single agent activity of all these drugs is very low and they are generally considered to be non-active agents in MM [4][5][6][7][8][9][10][11]. Thus, it is necessary to develop new drugs or combinations against MM.…”

Section: Introductionmentioning

confidence: 99%

Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma

et al. 2006

View full text Add to dashboard Cite

“…However, detorubicin (14) and pirarubicin (15) may be confined with RRs of about 20%, though having been evaluated in only one study each. The taxane docetaxel has revealed RRs varying from 5% to 23% (16, 17).…”

Section: Single‐agent Chemotherapymentioning

confidence: 99%

Current concepts in chemotherapy for malignant pleural mesothelioma

Sørensen

2008

Clinical Respiratory J

View full text Add to dashboard Cite

Objectives: The aim of this study was to provide an overview of the most active single agents and combination regimens in malignant pleural mesothelioma (MPM). Data Source: Literature on English-language trials in humans was searched on Medline until October 2007. Indexing terms were malignant pleural mesothelioma and chemotherapy. Study Selections: Trials with Ն15 patients and with data on activity were included. Results: Detorubicin and pirarubicin have response rates (RRs) of 22%-26%, epirubicin of 5%-15%, docetaxel of 5%-23% and vinorelbine of 24%. Other active agents were ifosfamide (3%-24%) and mitomycin C (21%). Carboplatin and cisplatin have an overall RR of 11% in three studies and 17% in four studies, respectively. Antimetabolites were active, including methotrexate (37%), raltitrexed (21%), edatrexate (16%-25%) and pemetrexed (15%). With respect to combination chemotherapy regimens, only cisplatin with either pemetrexed or raltitrexed has been compared with other substances, in both cases to cisplatin monotherapy. Both showed a survival advantage, which was statistically significant in the trial including pemetrexed, suggesting that chemotherapy improved survival in MPM. No studies have compared chemotherapy with the best supportive care alone, and none has compared different combination chemotherapy regimens with each other. Conclusions: A number of single-agent cytotoxics posess moderate activity against MPM. A number of platinum-based combination chemotherapy regimens show similar activities, but none has been compared with another combination. Cisplatin with either raltitrexed or pemetrexed has improved survival compared with cisplatin alone, and may be used as a reference treatment in randomized trials. Targeted agents should be explored in order to further improve the outcome.Please cite this paper as: Sørensen JB. Current concepts in chemotherapy for malignant pleural mesothelioma.

show abstract

Chemotherapie des malignen Pleuramesothelioms

Tomek¹,

Manegold

Pleuramesotheliom

View full text Add to dashboard Cite

Taxotere in malignant pleural mesothelioma. A phase II clinical trial

Cited by 6 publications

References 0 publications

Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma

Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma

Current concepts in chemotherapy for malignant pleural mesothelioma

Chemotherapie des malignen Pleuramesothelioms

Contact Info

Product

Resources

About